37
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

A Novel Nomogram to Predict Prognosis of Advanced Hepatocellular Carcinoma Treated with Intensity-Modulated Radiotherapy Plus Anti-PD1

, , , , , , , , , & show all
Pages 913-925 | Received 24 Feb 2024, Accepted 07 May 2024, Published online: 23 May 2024

Figures & data

Figure 1 Research technology roadmap.

Abbreviations: Anti-PD1, monoclonal antibody against programmed cell death 1; AUROC, the area under the subject received operating characteristic curve; BCLC, barcelona clinic liver cancer; HCC, hepatocellular carcinoma; IMRT, intensity-modulated radiotherapy.
Figure 1 Research technology roadmap.

Table 1 Baseline Characteristics of the Patients

Table 2 Summary of Efficacy Outcomes (N=93)

Figure 2 Kaplan–Meier analysis of overall and progression free survival.

Figure 2 Kaplan–Meier analysis of overall and progression free survival.

Figure 3 Best percentage change from baseline in sums of diameters of target lesions.

Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
Figure 3 Best percentage change from baseline in sums of diameters of target lesions.

Table 3 Univariate and Multivariate Cox Regression Analyses for Overall Survival and Progression-Free Survival

Figure 4 Survival nomogram (A). The total points of each patient can be used to predict survival outcome. ROC curves and AUROCs for the prediction of death within 1–3year among HCC patients after IMRT and anti-PD1 (B). Calibration curve for the prediction of death within 1 years among HCC patients after IMRT and anti-PD1 (C).

Abbreviations: Alb, albumin; AFP, alpha-fetoprotein; ANC3-4w, neutrophil count3-4w; PLR3-4w, platelet count3-4w / lymphocyte count3-4w.
Figure 4 Survival nomogram (A). The total points of each patient can be used to predict survival outcome. ROC curves and AUROCs for the prediction of death within 1–3year among HCC patients after IMRT and anti-PD1 (B). Calibration curve for the prediction of death within 1 years among HCC patients after IMRT and anti-PD1 (C).

Table 4 Adverse Events of Laboratory Testing After IMRT+ Anti-PD1 Treatment

Data Sharing Statement

The data underlying this article will be shared on reasonable request to the corresponding author.